Tin Mesoporphyrin IX (chloride)
(Synonyms: NSC 267099,SnMP) 目录号 : GC17594
A potent heme oxygenase inhibitor
Cas No.:106344-20-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ki = 14 nM
Tin Mesoporphyrin IX is a potent and competitive inhibitor of heme oxygenase (HO) activity.
Heme oxygenase or haem oxygenase (HO) is an enzyme catalyzing the degradation of heme. This produces biliverdin, ferrous iron, and carbon monoxide. There is limited evidence that levels of heme oxygenase are positive predictors of metabolic disease, insulin resistance, and metaflammation.
In vitro: Previous study found that Tin Mesoporphyrin IX was a potent competitive in-vitro inhibitor of enzyme activity when it was incubated with rat splenic microsomal heme oxygenase, with a Ki of 0.014 microM [1].
In vivo: Animal study showed that Tin Mesoporphyrin IX at 1 pmol/kg body wt could inhibit hepatic, renal, and splenic heme oxygenase activity in adult animals for extended periods of time. Tin Mesoporphyrin IX at 1 pmol/kg body wt also prevented the transient increase in serum bilirubin 24 h after birth in the rat neonate and significantly reduced the levels of serum bilirubin in aminolevulinic acid induced hyperbilirubinemia in the 7-day-old suckling neonate. Moreover, it was found that the tissue heme oxygenase activity decreased in both animal models of hyperbilirubinemia. Tin Mesoporphyrin IX treatment resulted in a prolonged increase in the heme saturation of hepatic tryptophan pyrrolase [1].
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Drummond, G. S.,Galbraith, R.A.,Sardana, M.K., et al. Reduction of the C2 and C4 vinyl groups of Sn-protoporphyrin to form Sn-mesoporphyrin markedly enhances the ability of the metalloporphyrin to inhibit in vivo heme catabolism. Archives of Biochemistry and Biophysics 255(1), 64-74 (1987).
| Cas No. | 106344-20-1 | SDF | |
| 别名 | NSC 267099,SnMP | ||
| 化学名 | (OC-6-13)-dichloro[7,12-diethyl-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanoato(4-)-κN21,κN22,κN23,κN24]-stannate(2-), dihydrogen | ||
| Canonical SMILES | [Cl-][Sn+4]123([N-]4C5=C(CCC([O-])=O)C(C)=C4C=C(C(CC)=C6C)[N]1=C6C=C(C(CC)=C7C)[N-]2C7=CC8=[N]3C(C(CCC([O-])=O)=C8C)=C5)[Cl-].[H+].[H+] | ||
| 分子式 | C34H34Cl2N4O4Sn • 2H | 分子量 | 754.3 |
| 溶解度 | ≤0.5mg/ml in DMSO;1mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.3257 mL | 6.6287 mL | 13.2573 mL |
| 5 mM | 0.2651 mL | 1.3257 mL | 2.6515 mL |
| 10 mM | 0.1326 mL | 0.6629 mL | 1.3257 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet